A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to assess the efficacy, safety, and tolerability of escalating transdermal doses of rotigotine (SPM 962) in subjects with early-stage Parkinson�s disease

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.